Preventing an innovation blackhole: Finding ways to optimize and accelerate regulatory pathways for orphan drugs in the EU 02-Nov-2020 By Jane Byrne A new multi-stakeholder group of experts has been set up to provide input and ideas in the context of the ongoing evaluation of the orphan medicinal products (OMP) regulation in Europe.
